The whole study sets out to provide the probability of developing TOX3-WDR5/ABCG2 signaling axis as the candidate cascade therapeutic targets or biomarkers for adjuvant treatment or survival prediction in CRC patients receiving postoperative chemotherapy or with metastasis. The gene discussed is WDR5; the disease is colorectal carcinoma.